相关实验视频

Updated: Sep 13, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

在体内皮层微结构:与老年人病和认知障碍的关系

Christin Schifani¹, John A E Anderson^1,2, Arash Nazeri³

¹Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.

Journal of neurochemistry

|August 2, 2025

概括

来自神经元定向分散和密度成像 (NODDI) 的自由水成像 (fISO) 显示出作为可访问的阿尔茨海默氏症生物标志物具有前途. fISO可能反映出tau病理和认知衰退,可能作为非PET成像代理.

科学领域:

神经成像是一种神经成像.
阿尔茨海默氏症疾病研究研究
生物标志物发现发现

背景情况:

定子发射断层扫描 (PET) 图像是阿尔茨海默病的一个关键生物标志物,但缺乏广泛的可访问性.
开发用于病理的非PET成像代理对于更广泛的临床应用至关重要.
神经元导向分散和密度成像 (NODDI) 提供了对大脑组织的微观结构见解.

研究的目的:

调查NODDI衍生指数 (ODI,NDI,fISO) 和TAU PET成像之间的关系.
探索这些微观结构指数与认知状态和宏观结构大脑变化的关联.
确定NODDI指数是否可以作为阿尔茨海默氏症病理学的可访问代理.

主要方法:

利用了ADNI-3数据集中的80名参与者的数据,使用扩散权重的MRI和tau PET扫描 ([18F]AV-1451).
使用多因素分析 (MFA) 来评估NODDI指数,皮质厚度/皮下体积 (CT/ScVol) 和 tau.之间的关系.
进行调解分析,以检查fISO在宏观结构和tau之间的关系中的作用.

主要成果:

自由水图像 (fISO) 显示了与tau PET信号的显著空间重叠,与初级MFA维度有很强的相关性.
fISO和tau与主要的MFA维度比宏观结构措施 (CT/ScVol) 有更强烈的关系.
fISO调解了CT/ScVol和tau之间的关系,解释了整个差异,表明fISO反映了tau的影响.

结论:

从NODDI衍生出的fISO可以作为阿尔茨海默氏症病理学的宝贵辅助生物标志物,补充tau PET.
皮层fISO,而不是宏观结构,可能更好地代表大脑对陶积累和认知变化的反应.
需要进一步的纵向研究来验证fISO作为可靠的,可访问的阿尔茨海默病生物标志物.

关键词:

诺迪尔是什么意思认知障碍是一种认知障碍.皮层的微观结构.这是一个dMRI.自由水的自由水.知道的知道的知道的

更多相关视频

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Cognitive Development During Adulthood

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...